Current issue #1, 2018

Russian pharma industry: 2017 results

The past year has not been a landmark for the pharma industry, however, it has been quite eventful in terms of the events directly affecting the industry. A traditional annual review by PharmVestnik covers drug marking, pricing, interchangeability, GMP, preferences, pharmacy practices, patent litigations etc.

[PharmVestnik # 02, 16/01/2018, p. 1, cont’d pp. 4-6]

// Medical Manufacturing

What the new state support measures would mean for Russian stent and catheter manufacturers

In early December 2017, another regulation setting forth preferences for local manufacturers of a specific medical device group was adopted. On the back of the ongoing disputes on the benefits and hazards of the “odd-man-out” mechanism, a “second-man-out” regulation has come into force having raised even more barriers for foreign manufacturers willing to enter the Russian hospital market. PharmVestnik explores the effects of this regulation for market players and patients.

[PharmVestnik # 02, 16/01/2018, p. 4]

// Budgets & Funding

Experts seek to set health budget priorities

On the back of chronic underfunding of the Russian healthcare, experts raise a question about top priorities in funding that would yield a maximum long-term effect, and would designate the areas not to save on. This topic was on the agenda of the recent conference on health system funding Finzdrav’2017 that discussed the 2018 health budget.

[PharmVestnik # 02, 16/01/2018, p. 7]

// Budgets & Funding

In 2018, the bulk of Pharma-2020 budget will be earmarked for state-supported projects

In late December 2017, the government...